Iterum Therapeutics Stock (NASDAQ:ITRM)
Previous Close
$1.77
52W Range
$0.81 - $3.02
50D Avg
$1.63
200D Avg
$1.40
Market Cap
$48.98M
Avg Vol (3M)
$2.88M
Beta
2.25
Div Yield
-
ITRM Company Profile
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.
ITRM Performance
Peer Comparison
| Ticker | Company |
|---|---|
| REVB | Revelation Biosciences, Inc. |
| FBIO | Fortress Biotech, Inc. |
| CTXR | Citius Pharmaceuticals, Inc. |
| JAGX | Jaguar Health, Inc. |
| DRMA | Dermata Therapeutics, Inc. |
| HOTH | Hoth Therapeutics, Inc. |
| ADIL | Adial Pharmaceuticals, Inc. |
| TNXP | Tonix Pharmaceuticals Holding Corp. |
| VRCA | Verrica Pharmaceuticals Inc. |
| EYEN | Eyenovia, Inc. |
| VINC | Vincerx Pharma, Inc. |